---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-411297"
form_type: "8-K"
ticker: "CELC"
cik: "0001603454"
company_name: "Celcuity Inc."
filed_at: "2026-10-02T12:05:13+00:00"
generated_at: "2026-10-12T14:31:50.652810+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Celcuity adds ex-Incyte/Celgene CFO David Gryska to board; cites first FDA approval of REVTORPYK

## Summary
- Board expanded from eight to nine members; David W. Gryska appointed effective October 1, 2026, serving through the 2027 Annual Meeting.
- Gryska was EVP and CFO of Incyte and SVP and CFO of Celgene, and earlier VP Finance/CFO at Scios and a partner at Ernst & Young.
- He joins the Audit and Compensation Committees and is deemed independent under Nasdaq listing standards and SEC rules.
- Pro-rated director pay: $70,000 annual cash retainer and $100,000 annual equity award; granted 893 RSUs vesting at the 2027 annual meeting or April 30, 2027.
- CEO Brian Sullivan links the hire to the company's transition to commercial stage after the first FDA approval for REVTORPYK in advanced breast cancer and gedatolisib development.

## SEC filing metadata
- accession: 0001193125-26-411297
- form_type: 8-K
- ticker: CELC
- cik: 0001603454
- company_name: Celcuity Inc.
- filed_at: 2026-10-02T12:05:13+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603454/000119312526411297/0001193125-26-411297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603454/000119312526411297/celc-20261001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-411297
- JSON: https://secwatch.observer/filing/0001193125-26-411297.json
- Plain text: https://secwatch.observer/filing/0001193125-26-411297.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.